Clinical Trial Update: Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls. [Phase 3]

View source ↗

Summary

A Phase 3 efficacy trial of IT MELPIDA for hereditary spastic paraplegia type 50 is currently recruiting, using concurrent controls.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Spastic Paraplegia Type 50

Drugs mentioned

• IT MELPIDA

Snippet

Sponsor: Elpida Therapeutics SPC | Conditions: Hereditary Spastic Paraplegia Type 50 | Phase 3 | Status: RECRUITING